Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 8/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655084 | 0.84 | NPY1R (0.47) | NPY1RSMN1; SMN2F10F2ALDH1A1 | |
| SCHEMBL10183595 | 0.84 | NPY1R (0.47) | NPY1RSMN1; SMN2F10F2ALDH1A1 | |
| SCHEMBL4870980 | 0.81 | F10 (0.41) | NPY1RSMN1; SMN2F10F2ALDH1A1 | |
| SCHEMBL5134064 | 0.81 | NPY1R (0.54) | NPY1RSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5119235 | 0.80 | NPY1R (0.41) | NPY1RSMN1; SMN2F10F2ALDH1A1 | |
| SCHEMBL5133148 | 0.80 | NPY1R (0.47) | NPY1RSMN1; SMN2F10ALDH1A1MEN1 | |
| SCHEMBL5132775 | 0.80 | ALDH1A1 (0.48) | NPY1RSMN1; SMN2F10ALDH1A1MEN1 | |
| SCHEMBL4802349 | 0.80 | NPY1R (0.45) | NPY1RSMN1; SMN2F10ALDH1A1MEN1 | |
| SCHEMBL649727 | 0.80 | ALDH1A1 (0.48) | NPY1RSMN1; SMN2F10ALDH1A1MEN1 | |
| SCHEMBL649728 | 0.80 | ALDH1A1 (0.48) | NPY1RSMN1; SMN2F10ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2006076597-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NPY1R 6/4885SMN1; SMN2 3953/4885F10 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.